Phase II clinical trials of finerenone were ARTS (Mineralocorticoid Receptor Antagonist Tolerability Study), ARTS-HF (MinerAlocorticoid Receptor Antagonist Tolerability Study-Heart Failure), and ARTS-DN (ARTS-Diabetic Nephropathy) [44–46]. This evidence concerns the gene NR3C2 and hydrops fetalis.